How to use the speech recognition tool?
NCT03584165
SOLSTICE
A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.
Type: Observational
Status of the trial: Active, Recruiting
Orphan Drug Recognition: Yes
Inclusion
- Opening Date: 2017-01-01
- Closing Date: 2027-03-27
Criteria
Inclusion: Subjects are willing and able to give informed consent for participation in the study, and have received a sub-retinal injection of AAV2-REP1 for CHM in an antecedent study.
Exclusion: There are no exclusion criteria for this study.
Children: No
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Retinal Rare Eye Diseases (WG1)